Pet Vaccine Market Size was valued at USD 11.7 Bn in 2024 and is predicted to reach USD 23.1 Bn by 2034 at a 7.4% CAGR during the forecast period for 2025-2034.
Pet vaccines encompass the creation, production, and distribution of vaccines intended to prevent the emergence of particular infectious illnesses in pets, with a focus on pets of all kinds. The growing number of pets, better understanding of pet health, and advancements in veterinary science have all contributed to this market's growth. Vaccine administration technological developments are also fueling market expansion. Vaccination procedures are becoming easier and more efficient because of innovations like oral vaccinations and needle-free vaccine administration devices.
Pets with needle fear or challenges to handle will especially benefit from these developments. Pet owners may now more easily obtain these necessary items thanks to the growing availability of vaccinations through various distribution methods, including internet platforms. The increasing popularity of pet insurance, which frequently pays for vaccinations, is another element pushing pet proprietors to vaccinate their animals regularly and propelling market expansion.
However, the strict legal framework controlling the creation and authorization of vaccines for livestock is one of the main obstacles. Regulatory procedures are frequently drawn out to guarantee both the security and effectiveness of vaccinations and require substantial expenditures in clinical investigations and research. This may raise the total expense of manufacturing and postpone the release of prospective vaccines into the marketplace. Additionally, especially in areas with smaller spending on healthcare and smaller financial resources, the high expense of vaccinations can be a significant barrier.
• Bayer AG
• Elanco US Inc.
• Merck KGaA
• Merial Inc.
• Virbac SA
• Zoetis Inc
• Phibro Animal Health Corporation
• Boehringer Ingelheim GmbH
• Tianjin Ringpu Bio-Technology Co., Ltd
• Vetoquinol SA
• Others
The pet vaccine market is segmented based on animal type, vaccine type, and mode of administration. Based on the animal type, the market is segmented into canine, feline, and equine.. The market is segmented by vaccine type into modified/ attenuated live, inactivated (killed), and others. By mode of administration, the market is segmented into injectable vaccines, intranasal Vaccines and others.
Canine is expected to hold a major global market share in 2024 in the pet vaccine market because of their overwhelming numbers and intimate interpersonal relationships. With rigorous vaccination requirements for illnesses including rabies, parvovirus illness, and canine pneumonia, canines are among the most common pets in the world. Their vulnerability to several zoonotic infections highlights the public health importance of canine immunization. Additionally, continuous improvements in the study of canine vaccines, such as customized ones, keep spurring innovation and market expansion.
The injectable vaccine segment is growing in the pet vaccine market because it is simple to administer, has an established reputation, and is efficient. Furthermore, injectable vaccinations are convenient for pet proprietors and veterinarian clinics due to their simplicity of carrying and storing. They maintain to rule the pet vaccine industry because they provide a tried-and-true approach to protecting companion animals' health.
The North American pet vaccine market is expected to register the highest market share in revenue in the near future. This can be attributed to the region's substantial ownership of animal paces, sophisticated veterinary treatment facilities, and the robust presence of major industries. Pet owners are very conscious of the value of immunizations, and the United States has widely recognized veterinary healthcare facilities.
The major driver includes pet humanity and the corresponding increase in spending on pet wellness. In addition, the Asia Pacific is expected to grow rapidly in the pet vaccine market due to the expanding adoption of animals, increasing financial resources, and greater knowledge of pet hygiene. The need for pet vaccinations in this area is anticipated to be driven by the expanding pet adoption trend and the increased emphasis on preventative healthcare.
• In September 2024, Bayer declared its firm had secured a unique permit for an innovative biology pesticide by signing a deal with AlphaBio Command, a UK-based company. The newly developed good is expected to be the initial for crops, such as grains and oilseed rape, to be made affordable. This new pesticide was found by AlphaBio, for which Bayer distributes FLiPPER, a successful bioinsecticide-acaricide. Its initial launch is scheduled to take place, assuming further investigation and authorization.
• In October 2024, Merck and Gilead Sciences, Inc. revealed the findings of the second section of the research program assessing a mixture of lenacapavir, a first-in-class HIV-1 infection capstone preventive and islatravir, an investigational amino acid transcription migration drug.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 11.7 Billion |
| Revenue Forecast In 2034 | USD 23.1 Billion |
| Growth Rate CAGR | CAGR of 7.4% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Animal Type, By Vaccine Type, By Mode of Administration and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Bayer AG, Elanco US Inc., Merck KGaA, Merial Inc., Virbac SA, Zoetis Inc, Phibro Animal Health Corporation, Boehringer Ingelheim GmbH, Tianjin Ringpu Bio-Technology Co., Ltd, and Vetoquinol SA. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Pet Vaccine Market-By Animal Type
• Canine
• Feline
• Equine
Pet Vaccine Market-By Vaccine Type
• Modified/ Attenuated Live
• Inactivated (Killed)
• Other Vaccines
Pet Vaccine Market-By Mode of Administration
• Injectable Vaccines
• Intranasal Vaccines
• Others
Pet Vaccine Market-By Region
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.